Psilocybin for distress in people with serious, life-limiting illness
Treatments studied
Part of Mental health clinical trials.
This Phase 2 study tests whether psilocybin therapy can reduce deep distress (“demoralization”) in people receiving palliative (comfort-focused) care. It may help with mood and well-being, but you must meet safety and medication requirements to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign and understand the study consent form, or have decision-making ability to consent
- Your life expectancy is about 2 years or less, due to a life-threatening illness
- You have moderate-to-severe demoralization (feeling deeply discouraged or worn down)
- You can take study medicines by mouth (capsules and/or liquid)
- You are currently a patient at a site already involved in the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a medicine called psilocybin, given with talk therapy, can safely help people with advanced cancer who feel very demoralized. Demoralization is a deep sense of hopelessness or loss of meaning. The goal is to see if this treatment can improve your emotional well-being.
This study tests whether psilocybin (a hallucinogen) combined with psychological support can help reduce feelings of hopelessness and loss of meaning in people with advanced cancer. It aims to see if this treatment can improve emotional well-being and quality of life.
This Phase 2 study tests how LSD may affect comfort and quality of life for people with advanced or end-stage life-limiting illness. It also checks whether the medicine is safe and can be given in a controlled way in palliative care settings.
This trial tests whether a single dose of psilocybin, given while you are under anesthesia, can help treat major depression. You will be monitored closely during and after the session.
This trial tests whether very low doses of psilocybin (a psychedelic substance) can help reduce emotional distress in people with a life-limiting illness. If you are receiving palliative care and feeling anxious or depressed, this study might offer a way to explore a new treatment option.
This trial tests whether a single dose of psilocybin (a psychedelic medicine) can help reduce depression and distress in people with advanced lung disease, ALS, multiple sclerosis, or Parkinson's. You would receive preparation, the drug, and follow-up support in a safe, supervised setting.
Hear when a new Demoralization trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.